Promising Tools in Prostate Cancer Research: Selective Non-Steroidal Cytochrome P450 17A1 Inhibitors

Research output: Contribution to journalJournal articleResearchpeer-review

Standard

Promising Tools in Prostate Cancer Research : Selective Non-Steroidal Cytochrome P450 17A1 Inhibitors. / Bonomo, Silvia; Hansen, Cecilie H; Petrunak, Elyse M; Scott, Emily E; Styrishave, Bjarne; Jørgensen, Flemming Steen; Olsen, Lars.

In: Scientific Reports, Vol. 6, 29468, 12.07.2016.

Research output: Contribution to journalJournal articleResearchpeer-review

Harvard

Bonomo, S, Hansen, CH, Petrunak, EM, Scott, EE, Styrishave, B, Jørgensen, FS & Olsen, L 2016, 'Promising Tools in Prostate Cancer Research: Selective Non-Steroidal Cytochrome P450 17A1 Inhibitors' Scientific Reports, vol. 6, 29468. https://doi.org/10.1038/srep29468

APA

Bonomo, S., Hansen, C. H., Petrunak, E. M., Scott, E. E., Styrishave, B., Jørgensen, F. S., & Olsen, L. (2016). Promising Tools in Prostate Cancer Research: Selective Non-Steroidal Cytochrome P450 17A1 Inhibitors. Scientific Reports, 6, [29468]. https://doi.org/10.1038/srep29468

Vancouver

Bonomo S, Hansen CH, Petrunak EM, Scott EE, Styrishave B, Jørgensen FS et al. Promising Tools in Prostate Cancer Research: Selective Non-Steroidal Cytochrome P450 17A1 Inhibitors. Scientific Reports. 2016 Jul 12;6. 29468. https://doi.org/10.1038/srep29468

Author

Bonomo, Silvia ; Hansen, Cecilie H ; Petrunak, Elyse M ; Scott, Emily E ; Styrishave, Bjarne ; Jørgensen, Flemming Steen ; Olsen, Lars. / Promising Tools in Prostate Cancer Research : Selective Non-Steroidal Cytochrome P450 17A1 Inhibitors. In: Scientific Reports. 2016 ; Vol. 6.

Bibtex

@article{8248f08e2cad4798aff65673f420592b,
title = "Promising Tools in Prostate Cancer Research: Selective Non-Steroidal Cytochrome P450 17A1 Inhibitors",
abstract = "Cytochrome P450 17A1 (CYP17A1) is an important target in the treatment of prostate cancer because it produces androgens required for tumour growth. The FDA has approved only one CYP17A1 inhibitor, abiraterone, which contains a steroidal scaffold similar to the endogenous CYP17A1 substrates. Abiraterone is structurally similar to the substrates of other cytochrome P450 enzymes involved in steroidogenesis, and interference can pose a liability in terms of side effects. Using non-steroidal scaffolds is expected to enable the design of compounds that interact more selectively with CYP17A1. Therefore, we combined a structure-based virtual screening approach with density functional theory (DFT) calculations to suggest non-steroidal compounds selective for CYP17A1. In vitro assays demonstrated that two such compounds selectively inhibited CYP17A1 17α-hydroxylase and 17,20-lyase activities with IC50 values in the nanomolar range, without affinity for the major drug-metabolizing CYP2D6 and CYP3A4 enzymes and CYP21A2, with the latter result confirmed in human H295R cells.",
author = "Silvia Bonomo and Hansen, {Cecilie H} and Petrunak, {Elyse M} and Scott, {Emily E} and Bjarne Styrishave and J{\o}rgensen, {Flemming Steen} and Lars Olsen",
year = "2016",
month = "7",
day = "12",
doi = "10.1038/srep29468",
language = "English",
volume = "6",
journal = "Scientific Reports",
issn = "2045-2322",
publisher = "nature publishing group",

}

RIS

TY - JOUR

T1 - Promising Tools in Prostate Cancer Research

T2 - Selective Non-Steroidal Cytochrome P450 17A1 Inhibitors

AU - Bonomo, Silvia

AU - Hansen, Cecilie H

AU - Petrunak, Elyse M

AU - Scott, Emily E

AU - Styrishave, Bjarne

AU - Jørgensen, Flemming Steen

AU - Olsen, Lars

PY - 2016/7/12

Y1 - 2016/7/12

N2 - Cytochrome P450 17A1 (CYP17A1) is an important target in the treatment of prostate cancer because it produces androgens required for tumour growth. The FDA has approved only one CYP17A1 inhibitor, abiraterone, which contains a steroidal scaffold similar to the endogenous CYP17A1 substrates. Abiraterone is structurally similar to the substrates of other cytochrome P450 enzymes involved in steroidogenesis, and interference can pose a liability in terms of side effects. Using non-steroidal scaffolds is expected to enable the design of compounds that interact more selectively with CYP17A1. Therefore, we combined a structure-based virtual screening approach with density functional theory (DFT) calculations to suggest non-steroidal compounds selective for CYP17A1. In vitro assays demonstrated that two such compounds selectively inhibited CYP17A1 17α-hydroxylase and 17,20-lyase activities with IC50 values in the nanomolar range, without affinity for the major drug-metabolizing CYP2D6 and CYP3A4 enzymes and CYP21A2, with the latter result confirmed in human H295R cells.

AB - Cytochrome P450 17A1 (CYP17A1) is an important target in the treatment of prostate cancer because it produces androgens required for tumour growth. The FDA has approved only one CYP17A1 inhibitor, abiraterone, which contains a steroidal scaffold similar to the endogenous CYP17A1 substrates. Abiraterone is structurally similar to the substrates of other cytochrome P450 enzymes involved in steroidogenesis, and interference can pose a liability in terms of side effects. Using non-steroidal scaffolds is expected to enable the design of compounds that interact more selectively with CYP17A1. Therefore, we combined a structure-based virtual screening approach with density functional theory (DFT) calculations to suggest non-steroidal compounds selective for CYP17A1. In vitro assays demonstrated that two such compounds selectively inhibited CYP17A1 17α-hydroxylase and 17,20-lyase activities with IC50 values in the nanomolar range, without affinity for the major drug-metabolizing CYP2D6 and CYP3A4 enzymes and CYP21A2, with the latter result confirmed in human H295R cells.

U2 - 10.1038/srep29468

DO - 10.1038/srep29468

M3 - Journal article

VL - 6

JO - Scientific Reports

JF - Scientific Reports

SN - 2045-2322

M1 - 29468

ER -

ID: 169359405